Human papillomavirus types in 115,789 HPV-positive women: A meta-analysis from cervical infection to cancer

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2349-2359

  Guan, Peng ^a,b   Howell Jones, Rebecca ^a,c   Li, Ni ^a,d   Bruni, Laia ^e   De Sanjosé, Silvia ^e   Franceschi, Silvia ^a   Clifford, Gary M ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b CHINA MEDICAL UNIVERSITY   (China)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d CANCER HOSPITAL   (China)

^e Institut Catalan d'Oncologia   (Spain)

Author keywords

cervical cancer; epidemiology; genotype; human papillomavirus; meta analysis; precancerous cervical lesions

Indexed keywords

AFRICA; ARTICLE; ASIA; CANCER GRADING; CARCINOGENESIS; CENTRAL AMERICA; CONDYLOMA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; CYTOPATHOLOGY; DISEASE SEVERITY; FEMALE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SOUTH AMERICA; SQUAMOUS CELL; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS;

EID: 84867054433     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27485     Document Type: Article

References (31)

1. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V,. A review of human carcinogens, Part B: Biological agents. Lancet Oncol 2009; 10: 321-2.
2. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM,. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011; 128: 927-35.
3. Bulkmans N, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke A, Bulk S, Voorhorst F, Verheijen R, van Groningen K, Boon M, Ruitinga W, van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72.
4. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Hagmar B, Johansson B, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del Mistro A, Ghiringhello B, Girlando S, Gillio-Tos A, De Marco L, Naldoni C, Pierotti P, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010; 11: 249-57.
6. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE,. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol 2011; 12: 663-72.
7. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, Hingmire S, Malvi SG, Thorat R, Kothari A, Chinoy R, Kelkar R, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
8. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM,. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-90.
9. Einstein MH, Martens MG, Garcia FA, Ferris DG, Mitchell AL, Day SP, Olson MC,. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010; 118: 116-22.
10. Carozzi FM, Burroni E, Bisanzi S, Puliti D, Confortini M, Giorgi RP, Sani C, Scalisi A, Chini F,. Comparison of clinical performance of Abbott RealTime High Risk HPV test with that of hybrid capture 2 assay in a screening setting. J Clin Microbiol 2011; 49: 1446-51.
11. Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V, Silver JE, Bisht A, Labiad Y, Peck RB, Lim J, Jeronimo J, et al. Feasibility study of a human papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and cancer. J Clin Microbiol 2010; 48: 4646-8.
12. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM,. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
13. Clifford GM, Smith JS, Plummer M, Muñoz N, Franceschi S,. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88: 63-73.
14. Clifford GM, Smith JS, Aguado T, Franceschi S,. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5.
15. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM,. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 1157-64.
16. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjosé S,. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
17. Williams RL,. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56: 645-6.
18. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
19. Schiffman M, Glass AG, Wentzensen N, Rush BB, Castle PE, Scott DR, Buckland J, Sherman ME, Rydzak G, Kirk P, Lorincz AT, Wacholder S, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-409.
20. Kjaer SK, Frederiksen K, Munk C, Iftner T,. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst 2010; 102: 1478-88.
21. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Hansson BG, Rylander E, Dillner J,. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007; 97: 129-32.
22. Chen HC, Schiffman M, Lin CY, Pan MH, You SL, Chuang LC, Hsieh CY, Liaw KL, Hsing AW, Chen CJ,. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst 2011; 103: 1387-96.
23. Clifford G, Franceschi S,. Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix. Int J Cancer 2008; 122: 1684-5.
24. Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, et al. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer 2011; 128: 1344-53.
25. Matsumoto K, Oki A, Furuta R, Maeda H, Yasugi T, Takatsuka N, Mitsuhashi A, Fujii T, Hirai Y, Iwasaka T, Yaegashi N, Watanabe Y, et al. Predicting the progression of cervical precursor lesions by human papillomavirus genotyping: a prospective cohort study. Int J Cancer 2011; 128: 2898-910.
26. Soderlund-Strand A, Eklund C, Kemetli L, Grillner L, Tornberg S, Dillner J, Dillner L,. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 2011; 205: 145.e1-145.e6.
27. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, Schiffman M, Wacholder S, Allen RA, Block I, Downing K, Jeronimo J, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev 2009; 18: 113-20.
28. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, Snijders JF, Petry KU, Kruger KS, Munk C, Iftner T,. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 2008; 80: 1264-74.
29. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D,. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-55.
30. Tjalma WA, Depuydt CE, Stoler MH, Wright TL,. Don't forget HPV-45 in cervical cancer screening. Am J Clin Pathol 2012; 137: 161-2.
31. Qiao YL, Sellors JW, Eder PS, Bao YP, Lim JM, Zhao FH, Weigl B, Zhang WH, Peck RB, Li L, Chen F, Pan QJ, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 929-36.